PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsparaproteinemias
MeSH D010265 - paraproteinemias
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D001796:Blood protein disorders
1 Company
1 Drug
$
Success rate
D007160:Immunoproliferative disorders
1 Company
1 Drug
$
Success rate
D010265: 
Paraproteinemias
1 Company
1 Drug
$
Success rate
D000075122:Smoldering multiple myeloma
0 Companies
0 Drugs
Success rate
D003449:Cryoglobulinemia
4 Companies
6 Drugs
$
Success rate
D006362:Heavy chain disease
0 Companies
0 Drugs
Success rate
D008258:Waldenstrom macroglobulinemia
24 Companies
5 Drugs
$
Success rate
D008998:Monoclonal gammopathy of undetermined significance
0 Companies
0 Drugs
Success rate
D009101:Multiple myeloma
80 Companies
34 Drugs
$
Success rate
D016878:Poems syndrome
0 Companies
0 Drugs
Success rate
D000075363:Immunoglobulin light-chain amyloidosis
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
92%
11/12
Phase 2
4%
1/26
Phase 3
50%
1/2
Approved: 1Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bristol Myers Squibb
Idecabtagene vicleucel
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use